<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>72</volume><submitter>Gonye AL</submitter><funding>National Institutes of Health National Cancer Institute</funding><funding>US Department of Defense Prostate Cancer Research Program</funding><pubmed_abstract>Chemotherapy resistance remains a critical barrier in cancer treatment, partly driven by polyploid cells that survive therapy and contribute to tumor recurrence. Here, we investigated epigenomic and transcriptional changes associated with cisplatin-surviving polyploid cells compared to parental cancer cells in prostate cancer (PC3) and triple-negative breast cancer (MDA-MB-231) cell lines. We observed persistent dysregulation of chromatin compaction and altered nuclear structure in polyploid cells following cisplatin treatment. Genome-wide chromatin accessibility profiling via ATAC-seq revealed significant remodeling, notably decreased promoter accessibility at proliferation-associated loci and increased accessibility of distal regulatory elements linked to inflammation and stress response</pubmed_abstract><journal>Neoplasia (New York, N.Y.)</journal><pagination>101268</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12857548</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Polyploid cisplatin-resistant cancer cells have altered nuclear organization and epigenomic status.</pubmed_title><pmcid>PMC12857548</pmcid><pubmed_authors>Cherry C</pubmed_authors><pubmed_authors>Orzolek L</pubmed_authors><pubmed_authors>Butler G</pubmed_authors><pubmed_authors>Pienta KJ</pubmed_authors><pubmed_authors>Amend SR</pubmed_authors><pubmed_authors>Gonye AL</pubmed_authors><pubmed_authors>Truskowski K</pubmed_authors><pubmed_authors>Loftus LV</pubmed_authors><pubmed_authors>Patatanian M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Polyploid cisplatin-resistant cancer cells have altered nuclear organization and epigenomic status.</name><description>Chemotherapy resistance remains a critical barrier in cancer treatment, partly driven by polyploid cells that survive therapy and contribute to tumor recurrence. Here, we investigated epigenomic and transcriptional changes associated with cisplatin-surviving polyploid cells compared to parental cancer cells in prostate cancer (PC3) and triple-negative breast cancer (MDA-MB-231) cell lines. We observed persistent dysregulation of chromatin compaction and altered nuclear structure in polyploid cells following cisplatin treatment. Genome-wide chromatin accessibility profiling via ATAC-seq revealed significant remodeling, notably decreased promoter accessibility at proliferation-associated loci and increased accessibility of distal regulatory elements linked to inflammation and stress response</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Feb</publication><modification>2026-06-10T08:53:44.741Z</modification><creation>2026-06-10T03:12:18.535Z</creation></dates><accession>S-EPMC12857548</accession><cross_references><pubmed>41570447</pubmed><doi>10.1016/j.neo.2025.101268</doi></cross_references></HashMap>